GlassScriptPhysician profile
Mohammad M Meratee
NPI 1164641510
$13,941.77
in general payments reported to CMS, 2019-2025
45 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $874 · 2021: $2,623 · 2022: $3,010 · 2023: $2,021 · 2024: $1,973 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,967 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,966.79 |
| Education | $210.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,938.72 | 2021-2025 | |
| Biogen, INC. | $1,149.77 | 2019-2025 | Vumerity, Tysabri |
| Ucb, INC. | $948.94 | 2021-2025 | Briviact, Cimzia, Nayzilam |
| Amgen INC. | $878.03 | 2019-2025 | Uplizna |
| Neurelis, INC. | $777.51 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $598.89 | 2021-2025 | |
| Pfizer INC. | $469.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $415.56 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $407.41 | 2019-2025 | Ultomiris |
| Allergan, INC. | $342.32 | 2019-2021 | |
| Genentech USA, INC. | $340.58 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $338.33 | 2021-2025 | |
| Lilly USA, LLC | $329.74 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Supernus Pharmaceuticals, INC. | $324.29 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $311.43 | 2020-2021 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Meratee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.